Logo
  • Main site
  • ALL
  • Caption: Executive Vice President, Product Supply, Quality & IT
    Extension: jpeg
    Caption: Executive Vice President, Product Supply, Quality & IT
    Extension: jpeg
    Caption: Executive vice president and head of Commercial Strategy & Corporate Affairs
    Extension: jpeg
    Caption: Executive vice president, head of Development
    Extension: jpeg
    Caption: Executive Vice President for Research & Early Development and Chief Scientific Officer (CSO)
    Extension: jpeg
    Caption: Executive vice president and head of Commercial Strategy & Corporate Affairs
    Extension: jpeg
    Caption: President and Chief Executive Officer (CEO)
    Extension: jpeg
    Caption: Executive vice president, chief financial officer (CFO)
    Extension: jpeg
    Caption: Executive Vice President, People & Organisation
    Extension: jpeg
    Caption: President and Chief Executive Officer (CEO)
    Extension: jpeg
    Caption: Executive Vice President, International Operations
    Extension: jpeg
    Caption: Executive vice president, chief financial officer (CFO)
    Extension: jpeg
    Caption: Executive Vice President, International Operations
    Extension: jpeg
    Caption: Executive Vice President, Head of Biopharm
    Extension: jpeg
    Caption: Executive Vice President, People & Organisation
    Extension: jpeg
    Caption: Executive Vice President, International Operations
    Extension: jpeg
    Caption: Executive vice president, head of Development
    Extension: jpeg
    Caption: Executive Vice President, Head of Biopharm
    Extension: jpeg
    Caption: Executive Vice President, North America Operations
    Extension: jpeg
    Caption: Executive Vice President, North America Operations
    Extension: jpeg
    Caption: President and Chief Executive Officer (CEO)
    Extension: jpeg
    Caption: The Team Novo Nordisk mission is to inspire, educate and empower people affected by diabetes. When diagnosed with diabetes, many people think it means they won’t be able to live life the way they’d hoped. Team Novo Nordisk hopes to show the world what may be possible with diabetes.
    Extension: jpeg
    Extension: jpeg
    Extension: jpeg
    Extension: jpeg
    Caption: Final visual inspection of the glass containers by the human eye before shipping to custom-ers. Copyright SCHOTT AG, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk.
    Extension: jpeg
    Caption: Planting 65,000 m2 forest with 24,000 trees, 16 different types and mostly Nordic trees, on the grounds surrounding our site Måløv near Copenhagen. Purpose is to mitigate climate change, support biodiversity and protect the groundwater.
    Extension: jpeg
    Caption: Planting 65,000 m2 forest with 24,000 trees, 16 different types and mostly Nordic trees, on the grounds surrounding our site Måløv near Copenhagen. Purpose is to mitigate climate change, support biodiversity and protect the groundwater.
    Extension: jpeg
    Caption: A 672-acre solar panel installation in North Carolina, US, providing power to Novo Nordisk’s entire US operations from early 2020.
    Extension: jpeg
    Caption: A 672-acre solar panel installation in North Carolina, US, providing power to Novo Nordisk’s entire US operations from early 2020..
    Extension: jpeg
    Caption: A 672-acre solar panel installation in North Carolina, US, will provide power to Novo Nordisk’s entire US operations from early 2020.
    Extension: jpeg
    Caption: n May 2007, Novo Nordisk signed a partnership agreement with the Danish energy company DONG Energy. Novo Nordisk has pledged to convert all energy savings realised at its Danish production into the purchase of green electricity from the new offshore wind farm at Horns Rev in the North Sea.
    Extension: jpeg
    Caption: In May 2007, Novo Nordisk signed a partnership agreement with the Danish energy company DONG Energy. Novo Nordisk has pledged to convert all energy savings realised at its Danish production into the purchase of green electricity from the new offshore wind farm at Horns Rev in the North Sea. Photo Rights belong to DONG
    Extension: jpeg
    Caption: 100% automatic camera in-process inspection to check geometries and tolerances according to specification after hotforming. Copyright SCHOTT AG, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk.
    Extension: jpeg
    Caption: From glass tube to container: neck forming is a controlled temperature process Copyright SCHOTT AG, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk. Copyright SCHOTT AG, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk.
    Extension: jpeg
    Caption: Glass containers are transported without glass-to-glass contact for further refinement and quality control. Copyright SCHOTT AG, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk.
    Extension: jpeg
    Caption: Long-term ambition is to provide access to affordable care to vulnerable patients in every country and accelerate prevention to halt the rise of diabetes. Photo: Roshni from India has diabetes type 1
    Extension: jpeg
    Caption: Long-term ambition is to provide access to affordable care to vulnerable patients in every country and accelerate prevention to halt the rise of diabetes. Photo: Cambie St, MT Pleasant, Vancouver, Canada
    Extension: jpeg
    Caption: Long-term ambition is to provide access to affordable care to vulnerable patients in every country and accelerate prevention to halt the rise of diabetes.
    Extension: jpeg
    Caption: More than four in five of these deaths are in low- and middle-income countries where access to essential medicines is inadequate. Zeana Masoud Said lives in Tanzania. She has type 1 diabetes and hypertension.
    Extension: jpeg
    Caption: More than four in five of these deaths are in low- and middle-income countries where access to essential medicines is inadequate. Daw Thein Yi lives in Myanmar. She has type 2 diabetes and lung cancer.
    Extension: jpeg
    Extension: jpeg
    Caption: Diabetes R&D, a high-accuracy digital micrometer for making oral tablets, at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Growth disorders R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Growth disorders R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Haemophilia R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Haemophilia R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Obesity R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: R&D at Novo Nordisk Oxford Research Centre, University of Oxford
    Extension: jpeg
    Caption: Obesity R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Long-term ambition is to provide access to affordable care to vulnerable patients in every country and accelerate prevention to halt the rise of diabetes.
    Extension: jpeg
    Caption: Oral semaglutide in a tablet
    Extension: jpeg
    Caption: Diabetes R&D at Novo Nordisk A/S, Denmark, 2016
    Extension: jpeg
    Caption: Diabetes R&D at Novo Nordisk A/S, Måløv, Denmark
    Extension: jpeg
    Extension: jpeg
    Caption: Novo Nordisk Research Center, Seattle, US
    Extension: jpeg
    Caption: Haemophilia R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: Growth disorders R&D at Novo Nordisk A/S, Måløv, Denmark, 2015
    Extension: jpeg
    Caption: New needle designed for use with the insulin delivery device FlexPen® and Victoza® Pen. The needle, which has a simple ‘just twist’ attachment and detachment, makes injection easier for people with diabetes
    Extension: jpeg
    Caption: NordiPen® with human growth hormone for treatment of growth disorders.
    Extension: jpeg
    Extension: jpeg
    Extension: png
    Caption: NovoFine® Autocover® was the world's first safety pen needle, designed to help prevent accidental needlestick injuries.
    Extension: jpeg
    Extension: jpeg
    Caption: Glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet
    Extension: jpeg
    Caption: NovoRapid® PumpCart (Zinc# HQMMA/NR/1014/0187b date of approval: October 2014)
    Extension: jpeg
    Caption: Glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet
    Extension: jpeg
    Extension: jpeg
    Caption: NovoPen® 5 is the culmination of more than 25 years of NovoPen® experience. With the additional benefit of an easy-to-use memory function, it builds on the strong design and performance of its predecessor, NovoPen® 4. 
    Extension: jpeg
    Caption: Treatment of haemophilia patient.
    Extension: jpeg
    Caption: NovoPen® 4 is a durable insulin pen which allows the patients to change their insulin cartridge while retaining the same pen.
    Extension: jpeg
    Extension: jpeg
    Caption: Insulin pen specifically designed to meet the needs of children with diabetes. First ever insulin pen to offer a combination of a memory function with a half-unit dosing option.
    Extension: jpeg
    Caption: FlexTouch® is a disposable, prefilled pen with no push-button extension
    Extension: jpeg
    Extension: jpeg
    Caption: FlexPen® is a prefilled insulin or GLP-1 pen
    Extension: jpeg
    Caption: An additional feature of the NovoPen® Echo is the option of customising the look of the pen with a number of colourful skins.
    Extension: jpeg
    Caption: NordiFlex PenMate® with automatic needle insertion accessory for users of NordiFlex® who prefer a hidden needle when injecting.
    Extension: jpeg
    Caption: With human growth hormone for treatment of growth disorders.
    Extension: jpeg
    Extension: png